CalRegen, Inc is a start-up biotechnology company formed on the discovery of calreticulin (CRT), as a novel biotherapeutic that has unique, diverse and broad ranging tissue regenerative qualities that will be developed for different indications including chronic wound healing, epidermal appendage (hair follicle) neogenesis, improving the cosmetic architecture of the skin, and healing of ophthalmic ulcers.…